Century Therapeutics, a biotechnology company focused on iPSC-derived cell therapies for immuno-oncology and autoimmune diseases, has announced a significant collaboration to advance its lead candidate, CNTY-101. The company has partnered with renowned experts Professors Georg Schett and Andreas Mackensen of Friedrich-Alexander University Erlangen-Nürnberg for an investigator-initiated Phase 1/2 trial (IIT) called the CARAMEL trial.
This IIT marks the first evaluation by the Schett/Mackensen group of an allogeneic (off-the-shelf) iPSC-derived CD19-directed NK cell therapy in autoimmune diseases. The CARAMEL trial will mirror Century’s ongoing Phase 1 CALiPSO-1 trial (NCT06255028) by assessing the safety, efficacy, and key translational data of CNTY-101 in several B-cell mediated autoimmune conditions: systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis.
Brent Pfeiffenberger, CEO of Century Therapeutics, emphasized the importance of this collaboration, stating that it validates the potential of CNTY-101 in autoimmune settings. He highlighted CNTY-101’s unique advantages as an iPSC-derived NK cell therapy incorporating Century’s Allo-Evasion™ technology, which allows for precise control over drug exposure. He also noted the encouraging preclinical and clinical data demonstrating anti-B cell activity and a favorable safety profile. The company anticipates valuable insights from the CARAMEL trial, which will complement their ongoing CALiPSO-1 trial and drive key milestones in the coming year.
Dr. Andreas Mackensen explained the rationale behind using allogeneic iPSC-derived cell therapy like CNTY-101, emphasizing the advantages of an “off-the-shelf” product. He pointed out the elimination of logistical challenges associated with autologous (patient-derived) cell therapies, such as apheresis (blood collection), the removal of washout periods (time needed for prior treatments to clear the system), and the potential for outpatient administration. Dr. Mackensen expressed enthusiasm for the partnership with Century and their shared goal of addressing significant unmet needs for patients with these serious autoimmune diseases.
The Schett/Mackensen group is a recognized leader in cell therapy for autoimmune diseases. Their 2022 research demonstrated the effectiveness of autologous CD19 CAR-T cell therapy in achieving deep B-cell depletion and inducing long-term, drug-free remission in patients with severe autoimmune conditions, paving the way for further investigation of cell therapies in this area. The CARAMEL trial with Century is expected to begin in mid-2025, pending clinical trial authorization (CTA) approval.
In addition to the CARAMEL IIT, Century plans to expand its CALiPSO-1 clinical trial to include sites in select European countries. The company will provide an update on the timing of initial clinical data from CALiPSO-1 once patient enrollment has stabilized across the different indications being studied.

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE